AU6002396A - Method for the detection of compounds that modulate the effects of the obese protein - Google Patents
Method for the detection of compounds that modulate the effects of the obese proteinInfo
- Publication number
- AU6002396A AU6002396A AU60023/96A AU6002396A AU6002396A AU 6002396 A AU6002396 A AU 6002396A AU 60023/96 A AU60023/96 A AU 60023/96A AU 6002396 A AU6002396 A AU 6002396A AU 6002396 A AU6002396 A AU 6002396A
- Authority
- AU
- Australia
- Prior art keywords
- protein
- compound
- response element
- promoter
- stat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Method for the detection of compounds that modulate the effects of the obese protei n
The invention relates to a novel method and more particularly to a method for the detection of compounds that mimic, potentiate or inhibit the physiological effects of the ob-protein
The ob-protein (or leptin) is a secreted hormone that acts as signal from adipose tissue to other organs to regulate weight and energy balance (Zhang et. al., Nature, 1994, 372, 425). Additional roles for the ob-protein in hematopoietic and reproductive function have been suggested (Cioffi et. al. Nature Medicine, 1996, 2(5), 585). Protein molecules that contain a core composed of four α-helices forming a bundle of up-up-down-down topology comprise of a family of cytokines and growth factors. Proteins of this family cause homo- and hetero-oligermerisation of membrane receptors known to activate kinase cascades resulting in gene transcription. Receptors of the family which are activated by oligermerisation fall into two broad classes; those such as epidermal growth factor, which possess integral tyrosine kinase activity in their intracellular domains (A. Ullrich & J. Schlessinger, Cell, 1990, 61, 203-212), and those such as IL4 and erythropoietin, which lack this activity and mediate their response by way of an associated protein tyrosine kinase (J.N. Ihle et al., TIBS, 1994, 19, 222-227). Both receptor subtypes are activated by cytokines, but the 4-helix bundle proteins activate only the non-integral tyrosine kinase subtype. The non- integral protein tyrosine kinase receptors generally act through a pathway involving Janus kinase (JAK) and their associated signal transducers and activators of transcription (STAT) proteins. On activation STAT proteins bind to DNA response elements thereby controlling gene transcription. Oligonucleotide sequences comprising DNA regulatory elements of the general sequence TT(N)nAA have been identified (Seidel et al., Proc. Nat. Acad. Sci. USA., 1995, 92, 3041) as STAT response elements. These elements bind STAT proteins in response to signaling molecules such as cytokines.
In copending United Kingdom patent application number 9509164.1 we have described our discovery that the ob-protein is characterised by a four helix bundle tertiary structure. We now believe that the ob-protein interacts with a membrane bound receptor that activates a JAK-STAT kinase cascade and hence forms the basis for an assay system for the detection of compounds that mimic, potentiate or inhibit the physiological effects of the ob-protein. Such an assay has utility in selecting compounds for the treatment of weight, energy balance, hematopoietic, fertility and other disorders modulated by the "ob-protein". The assay is especially useful for selecting compounds for the treatment of those disorders related to obesity, anorexia, cachexia and diabetes.
Accordingly, the invention provides a method for the detection of a compound that mimics, potentiates or inhibits the physiological effect of the ob-protein, which method comprises:
(a) for a compound which mimics the physiological effect of the ob-protein, assessing the effect of the compound upon an ob-protein activated signal transducer and
activator of transcription (STAT) DNA response element coupled to a reporter gene; or
(b) for a compound which potentiates or inhibits the physiological effect of the ob- protein, assessing the effect of the compound upon the response provided by ob protein upon an ob-protein activated STAT DNA response element coupled to a reporter gene; the response element and the reporter being expressed in an ob-protein responsive cell line.
Suitably, the response element is coupled to a promoter gene, preferably a minimal promoter.
A suitable response element is a nucleotide of formula TT(N)n AA, where N is any nucleotide and n is 4, 5 or 6.
A favoured response element is selectively activated by the intracellular events mediated the by the ob-protein interacting with its receptor. Such selective response elements can be determined by examining the relative activation of a range of response element-reporter gene constructs when transfected into an ob-responsive cell line by the ob-protein versus other cytokines.
A favoured response element is a nucleotide of formula TT(N)n AA, where N is any nucleotide and n is 5. A further suitable response element is TTCCCGGAA.
A further suitable response element is that region of the promoter of a gene regulated by the ob-protein that is required for STAT interactions. This gene will depend on the particular therapeutic use of the compounds to be selected by the assay.
A suitable reporter gene is firefly luciferase or chloramphenicol acetyltransferase enzyme.
A suitable promoter is a minimal promoter such as the herpes simplex virus thymidine kinase or SV40 promoter.
An example of an "ob-responsive" cell line is a liver or liver hepatoma derived cell line. Liver or liver hepatoma cell lines are available from either the American Type Culture Collection (ATCC) or the Eurpean Collection of Animal Cell Cultures (ECACC). An example of one such cell line is Hep G2 (hepatocellular carcinoma, human) which is available from the ATCC (HB-8065). The Hep G2 ceU line is disclosed and claimed by US patent 4393133. A further example of an "ob-responsive" cell line is the rat-1 fibroblast (Kroder et. al., Exp. Clin. Endocήnol. Diabetes, 1996, 104 (suppl 2), 66). A ratl fibroblast cell line is available from the ATCC (CRL-2210).
Other responsive cell lines can be identified using a displacement binding assay. Although binding may not be to a functional long form of the receptor, which is the form that transmits a signal to the cytoplasm. Identification of a functional long form of the receptor may be by PCR or Northern blot analysis (eg. Human ob-receptor: Tartaglia et al, Cell, 1995, 83, 1263). Ultimately responsive cells are detected by monitoring cellular events in the presence of varying concentrations of leptin.
Potential methods for identifying candidate cell lines or monitoring these cellular events include the following:-
1. Microphysiometer: This method detects small changes in pH resulting from biochemical changes in the cell. Ob-protein responsive cells upon stimulation may undergo biochemical changes that cause a small change in the extracellular acidification rate which can be detected by a silicon microphysiometer. The microphysiometer biosensor methodology has been reviewed by McConnell, Science, 1992, 257, 1906.
2. Electrophoretic mobility shift assay (EMS A): Nuclear extracts from cells after treatment with ob-protein are mixed with radiolabeled oligonucleo tides containing a promiscuous or specific STAT response element DNA sequence. Extracts from cells that respond to the ob-protein may cause a gel shift of the oligonucleotide for the STAT response element.
References: Book "Recombinant DNA", 2nd Edition, Watson et al. , 1992, Page 158; Lamb et al., Blood, 1994, 83, 2063;
3. Measurement of protein phosphorylation assay: The coupling of receptor activation to the final response through tyrosine phosphorylation of intracellular proteins may be assayed by the use of antibodies recognising phosphorylated tyrosines. More specifically since the leptin receptor may stimulate tyrosine phosphorylation of the JAK/STAT pathway this method provides a method of detecting leptin response cell lines. Specific JAK/ STAT antibodies may be used alongside antibodies for tyrosine phosphorylation to detect leptin activation in a leptin responsive cell line. Inhibition as well as stimulation of protein phosphorylation may occur. In particular, inhibition by the ob-protein of insulin stimulated phosphorylation of the insulin receptor and insulin receptor substrate- 1 has been shown in rat-1 fibroblasts overexpressing insulin receptors (Kroder et. al 1996, Exp. Clin. Endocήnol. Diabetes, 104, suppl 2, p66)
4. Displacement binding: After incubation of cell lines with radiolabelled leptin, for example [^^^I]-leptin, the non-specific binding versus specific binding of leptin can studied by the addition of unlabelled leptin. A high specific to non-specific ratio binding suggests that the cell line may contain the leptin receptor.
5. Detection of the protein for a functional form, preferably a functional long form, of the ob-receptor by use of selective antibodies.
6. Detection of mRNA for a functional form, preferably a functional long form, of the ob-receptor by Northern, RT-PCR or "slot blot" analysis.
Cell lines known to be involved in controlling aspects of the particular disease state for which compounds are being sought are preferred.
Cells lines derived from liver, brain, or pancreatic tissue and fibroblasts are particularly useful for "ob-responsive" cells for the assaying of compounds directed at obesity and diabetes. Certain areas of the brain are the focus of weight controlling and energy balance regulating effects of the ob-protein. The liver controls many metabolic processes that modulate lipid and glucose levels. Cells derived from particular regions of these organs containing the appropriate endogenous JAKs, STAT proteins and
other intracellular proteins which are required for mediating the effects of the leptin are preferred.
The response element, the reporter, and preferably the promoter, are suitably incorporated into a vector capable of transfecting the ob-responsive cell line. Suitable vectors are commercially available vectors, such as pGL2-basic lucif erase vector (Promega).
A suitable configuration of the vector is the STAT DNA response element upstream of a promoter and a reporter gene. A more suitable configuration of the vector is the STAT DNA response element in multiple tandem repeats (2-10) upstream of a thymidine kinase promoter and a luciferase reporter gene
Vectors are constructed containing a reporter gene for example firefly luciferase or chloramphenicol acetyltransferase enzyme linked to a minimal promoter for example the herpes simplex virus thymidine kinase or S V40 promoter. The DNA fragments for the STAT response element are inserted into the vector using appropriate restriction enzyme sites upstream of the minimal promoter.
The response element, the reporter and the promoter, as required, are incorporated into the vector using conventional expression techniques, for example the DNA fragments for the response element may be inserted into the vector using appropriate restriction enzyme sites upstream of the minimal promoter. STAT response element-luciferase enzyme reporter systems can be constructed as described by Lamb et al., Blood, 1994, 8, 2063 and Seidel et al., Proc. Nat. Acad. Sci. USA., 1995, 92, 3041.
Ob-responsive cells are transfected with the STAT response element-minimal promoter-luciferase reporter constructs using standard methodology for example the calcium phosphate method (Graham and Van Der Eb, Virology, 1973, 52, 456). To correct for differences in transfection efficiency, the cells can be co-transfected with a reference plasmid expressing β-galactosidase activity. After a period of transfection (12-24 hours) the cells are treated with varying concentrations of compound and then harvested and lysed. The lysates are assayed for luciferase, and if appropriate β- galactosidase, activity. Potentiation or antagonist activity can be assayed by pre- or co-addition of an appropriate concentration of ob-protein to the compound under evaluation and measuring the potentiation or reduction in luciferase response relative to that of ob-protein alone. Standard methods exist for assaying luciferase enzyme activity for example Ow et al., Science, 1986, 234, 856 and de Wet et al., Mol. Cell Biol., 1987, 7, 725. as well as several commercial kits.
Stable cell lines can be generated by transfecting an "ob-responsive" cell line with the reporter construct and a selectable marker. Selectable markers are routinely used to generate stable cell lines as described in Recombinant DNA, 2nd edition, J.D. Watson et. al., 1992, page 216. These stably transfected cell lines can be used to generate high throughput assays for compounds that mimic, potentiate or block the physiological effects of the ob-protein.
The invention also extends to a compound that mimics, potentiates or inhibits the physiological effect of the ob-protein, when identified by the method disclosed herein.
The invention also extends to a kit of parts adapted for use in the method disclosed herein.
When used herein 'a compound which mimics the physiological effects of the ob-protein' refers to a compound which is capable of acting in the absence of the ob- protein to either stimulate the ob-protein receptor to provide substantially the same physiological effect as the ob protein or to activate a response down stream of this receptor (post-receptor).
When used herein 'a compound that potentiates the physiological effect of the ob-protein' refers to a compound which enhances the potency and/or maximal physiological effect of the ob-protein.
When used herein 'a compound that inhibits the physiological effect of the ob- protein1 refers to a compound which reduces or substantially blocks the physiological effect of the ob protein.
The following example illustrates the invention
Example
General Procedure: Ob-responsive cells are transfected with a reporter plasmid containing a STAT response element, in multiple tandem copies upstream of a minimal promoter for example herpes simplex thymidine kinase and a luciferase gene reporter constructusing standard methodology for example the calcium phosphate method (Graham and Van Der Eb, Virology, 1973, 52, 456). To correct for differences in transfection efficiency, the cells can be co-transfected with a reference plasmid expressing β-galactosidase activity. After a period of transfection (12-24 hours) the cells are treated with varying concentrations of compound and then harvested and lysed. The lysates are assayed for luciferase, and if appropriate β-galactosidase, activity. Antagonist activity can be assayed by pre- or co-addition of an appropriate concentration of ob-protein to the compound under evaluation and measuring the reduction in luciferase response relative to that of ob-protein alone. Standard methods exist for assaying luciferase enzyme activity for example Ow et al, Science, 1986, 234, 856 and de Wet et al., 1987, 7, 725. as well as several commercial kits.
Example
A liver hepatoma derived cell line is transfected with a reporter plasmid, pGL2-basic luciferase vector (promega) containing an insert of an oligonucleotide corresponding to a four fold tandem repeat of the STAT response element, TTCCCGGAA, upstream of the minimal promoter for herpes simplex thymidine kinase (-35 to +10) using standard methodology for example the calcium phosphate method (Graham and Van Der Eb, Virology, 1973, 52, 456). To correct for differences in transfection efficiency, the cells can be co-transfected with a reference plasmid expressing β-galactosidase activity. After a period of transfection (12-24 hours) the cells are treated with varying concentrations of compound and then harvested and lysed. The lysates are assayed for luciferase, and if appropriate β-galactosidase, activity. Antagonist activity can be assayed by pre- or co-addition of an appropriate concentration of ob-protein to the compound under evaluation and measuring the reduction in luciferase response relative to that of ob-protein alone. Standard methods exist for assaying luciferase enzyme activity for example Ow et al., Science, 1986, 234, 856 and de Wet et al., Mol. Cell Biol., 1987, 7, 725. as well as several commercial kits.
Claims (11)
1. A method for the detection of a compound that mimics, potentiates or inhibits the physiological effect of the ob-protein, which method comprises: (a) for a compound which mimics the physiological effect of the ob-protein, assessing the effect of the compound upon an ob-protein activated signal transducer and activator of transcription (STAT) DNA response element coupled to a reporter gene; or
(b) for a compound which potentiates or inhibits the physiological effect of the ob- protein, assessing the effect of the compound upon the response provided by ob protein upon an ob-protein activated STAT DNA response element coupled to a reporter gene; the response element and the reporter being expressed in an ob-protein responsive cell line.
2. A method according to claim 1, wherein the response element is coupled to a promoter gene, preferably a minimal promoter.
3. A method according to claim 2, wherein the response element is a nucleotide of formula TT(N)n AA, where N is any nucleotide and n is 4, 5 or 6, preferably 5.
4. A method according to claim 2, wherein the response element is a nucleotide of formula TTCCCGGAA.
5. A method according to claim 1 , wherein the reporter gene is firefly luciferase or chloramphenicol acetyltransferase enzyme.
6. A method according to claim 1 , wherein the promoter is the herpes simplex virus thymidine kinase or SV40 promoter.
7. A method according to claim 1, wherein the ob-responsive cell line is a liver or liver hepatoma derived cell line.
8. A method according to claim 1, wherein the response element, the reporter, and the promoter, are incorporated into a vector capable of transfecting the ob- responsive cell line.
9. A method according to claim 8, wherein the vectors pGL2-basic luciferase vector (Promega).
10. A method according to claim 8 or claim 9, wherein the configuration of the vector is such that the STAT DNA response element is upstream of the promoter and reporter gene.
11. A kit of parts adapted for use in the method for the detection of a compound that mimics, potentiates or inhibits the physiological effect of the ob-protein, which method comprises:
(a) for a compound which mimics the physiological effect of the ob-protein, assessing the effect of the compound upon an ob-protein activated signal transducer and activator of transcription (STAT) DNA response element coupled to a reporter gene; or
(b) for a compound which potentiates or inhibits the physiological effect of the ob- protein, assessing the effect of the compound upon the response provided by ob protein upon an ob-protein activated STAT DNA response element coupled to a reporter gene; the response element and the reporter being expressed in an ob-protein responsive cell line.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9510857 | 1995-05-30 | ||
| GBGB9510857.7A GB9510857D0 (en) | 1995-05-30 | 1995-05-30 | Novel assay |
| GBGB9511602.6A GB9511602D0 (en) | 1995-06-08 | 1995-06-08 | Novel assay |
| GB9511602 | 1995-06-08 | ||
| PCT/EP1996/002291 WO1996038586A1 (en) | 1995-05-30 | 1996-05-28 | Method for the detection of compounds that modulate the effects of the obese protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6002396A true AU6002396A (en) | 1996-12-18 |
| AU715215B2 AU715215B2 (en) | 2000-01-20 |
Family
ID=26307107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU60023/96A Ceased AU715215B2 (en) | 1995-05-30 | 1996-05-28 | Method for the detection of compounds that modulate the effects of the obese protein |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0832284A1 (en) |
| JP (1) | JPH11505725A (en) |
| KR (1) | KR19990022134A (en) |
| CN (1) | CN1192248A (en) |
| AU (1) | AU715215B2 (en) |
| BR (1) | BR9608686A (en) |
| CA (1) | CA2222409A1 (en) |
| CZ (1) | CZ379097A3 (en) |
| HU (1) | HUP9801744A3 (en) |
| MX (1) | MX9709360A (en) |
| NO (1) | NO975504D0 (en) |
| NZ (1) | NZ309777A (en) |
| PL (1) | PL323638A1 (en) |
| TR (1) | TR199701469T1 (en) |
| WO (1) | WO1996038586A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
| US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| JP2000511406A (en) * | 1996-04-22 | 2000-09-05 | メルク エンド カンパニー インコーポレーテッド | Leptin assay |
| US6007998A (en) * | 1996-04-22 | 1999-12-28 | Merck & Co., Inc. | Leptin assay |
| US6001816A (en) * | 1996-06-20 | 1999-12-14 | Merck & Co., Inc. | Gene therapy for leptin deficiency |
| JP2001503982A (en) * | 1996-11-01 | 2001-03-27 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Method for detecting a compound that modulates the effect of obesity (OB) protein |
| IT1293533B1 (en) * | 1997-07-14 | 1999-03-01 | Angeletti P Ist Richerche Bio | METHOD FOR THE SELECTION OF MOLECULES ABLE TO MIMIC, INHIBIT OR ENHANCE THE EFFECTS OF THE INTERACTION BETWEEN LEPTIN AND CELLS THAT |
| WO1999023493A1 (en) * | 1997-10-31 | 1999-05-14 | The Rockefeller University | Methods of identifying agents that modulate leptin activity |
| EP1053007A2 (en) * | 1998-02-11 | 2000-11-22 | Beth Israel Deaconess Medical Center | Methods and compositions for modulating leptin activity |
| GB9814199D0 (en) * | 1998-06-30 | 1998-08-26 | Univ Buckingham | Novel method |
| GB9828087D0 (en) * | 1998-12-18 | 1999-02-17 | Smithkline Beecham Plc | Novel method |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7795094A (en) * | 1993-09-15 | 1995-04-03 | New York University | Dna sequence which binds transcriptional regulatory proteins activated in response to various cytokines and uses thereof |
| JPH09500026A (en) * | 1994-04-14 | 1997-01-07 | リガンド・ファーマシューティカルズ・インコーポレーテッド | Cytokine-responsive DNA spacer regulatory element and method of use thereof |
-
1996
- 1996-05-28 AU AU60023/96A patent/AU715215B2/en not_active Ceased
- 1996-05-28 CN CN96195983A patent/CN1192248A/en active Pending
- 1996-05-28 CZ CZ973790A patent/CZ379097A3/en unknown
- 1996-05-28 JP JP8536176A patent/JPH11505725A/en active Pending
- 1996-05-28 KR KR1019970708613A patent/KR19990022134A/en not_active Application Discontinuation
- 1996-05-28 BR BR9608686A patent/BR9608686A/en active Search and Examination
- 1996-05-28 MX MX9709360A patent/MX9709360A/en unknown
- 1996-05-28 PL PL96323638A patent/PL323638A1/en unknown
- 1996-05-28 HU HU9801744A patent/HUP9801744A3/en unknown
- 1996-05-28 EP EP96917454A patent/EP0832284A1/en not_active Withdrawn
- 1996-05-28 WO PCT/EP1996/002291 patent/WO1996038586A1/en not_active Application Discontinuation
- 1996-05-28 NZ NZ309777A patent/NZ309777A/en unknown
- 1996-05-28 CA CA002222409A patent/CA2222409A1/en not_active Abandoned
- 1996-05-28 TR TR97/01469T patent/TR199701469T1/en unknown
-
1997
- 1997-11-28 NO NO975504A patent/NO975504D0/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9608686A (en) | 1999-07-06 |
| KR19990022134A (en) | 1999-03-25 |
| CN1192248A (en) | 1998-09-02 |
| EP0832284A1 (en) | 1998-04-01 |
| NZ309777A (en) | 2000-01-28 |
| HUP9801744A2 (en) | 1998-10-28 |
| CZ379097A3 (en) | 1998-05-13 |
| TR199701469T1 (en) | 1998-03-21 |
| HUP9801744A3 (en) | 2000-06-28 |
| WO1996038586A1 (en) | 1996-12-05 |
| AU715215B2 (en) | 2000-01-20 |
| JPH11505725A (en) | 1999-05-25 |
| NO975504L (en) | 1997-11-28 |
| MX9709360A (en) | 1998-02-28 |
| PL323638A1 (en) | 1998-04-14 |
| NO975504D0 (en) | 1997-11-28 |
| CA2222409A1 (en) | 1996-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Hepatic nuclear factor 3 is an accessory factor required for the stimulation of phosphoenolpyruvate carboxykinase gene transcription by glucocorticoids. | |
| Chesnokov et al. | p53 inhibits RNA polymerase III-directed transcription in a promoter-dependent manner | |
| AU715215B2 (en) | Method for the detection of compounds that modulate the effects of the obese protein | |
| Brasier et al. | Synergistic enhansons located within an acute phase responsive enhancer modulate glucocorticoid induction of angiotensinogen gene transcription | |
| KIM et al. | Angiotensin II-responsive element is the insulin-responsive element in the adipocyte fatty acid synthase gene: role of adipocyte determination and differentiation factor 1/sterol-regulatory-element-binding protein 1c | |
| MXPA97009360A (en) | Method for the detection of compounds that modulate the effects of the obesi protein | |
| Chiles et al. | Cross-linking of surface Ig receptors on murine B lymphocytes stimulates the expression of nuclear tetradecanoyl phorbol acetate-response element-binding proteins. | |
| US6007998A (en) | Leptin assay | |
| Harada et al. | Osteogenic protein-1 up-regulation of the collagen X promoter activity is mediated by a MEF-2-like sequence and requires an adjacent AP-1 sequence | |
| Szebenyi et al. | Differential regulation of mannose 6-phosphate receptors and their ligands during the myogenic development of C2 cells. | |
| WO1998020158A1 (en) | Method for the detection of compounds that modulate the effects of the obese (ob) protein | |
| Monla et al. | Cell type-specific regulation of transcription by cyclic adenosine 3,'5'-monophosphate-responsive elements within the calcitonin promoter. | |
| RU2139936C1 (en) | Method of determining modulation effect of substance on interleukin-5 receptor-linked signal-transmission route in human or animal cell | |
| CA2194361A1 (en) | Method for identifying nucleic acids encoding c-fos promoter activating proteins | |
| Buchou et al. | Fibroblast growth factor‐dependent mitogenic signal transduction pathway in chemically transformed mouse fibroblasts is similar to but distinct from that initiated by phorbol esters | |
| US20020068300A1 (en) | Method for the detection of compounds that modulate the effects of the obese protein | |
| EP0914611A1 (en) | Leptin assay | |
| Quarles et al. | Developmental regulation of osteocalcin expression in MC3T3‐E1 osteoblasts: Minimal role of the proximal E‐box cis‐acting promoter elements | |
| US20030224456A1 (en) | Method for the detection of compounds that modulate the effects of the obese (OB) protein | |
| US20040038315A1 (en) | Novel method | |
| Cabanillas et al. | T3-activation of the rat growth hormone gene is inhibited by a zinc finger/homeodomain protein | |
| WO2000037675A2 (en) | Reporter gene assay for compounds which mimic or inhibit the physiological effect of the ob-protein | |
| MXPA99004184A (en) | Method for the detection of compounds that modulate the effects of the obese (ob) protein | |
| Catterall et al. | Differential regulation of specific gene expression in mouse kidney by androgens and antiandrogens | |
| Narayanan et al. | cAMP increases the expression of human angiotensinogen gene through a combination of cyclic AMP responsive element binding protein and a liver specific transcription factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |